These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7748304)

  • 1. Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption.
    Naranjo CA; Bremner KE
    Alcohol Alcohol Suppl; 1993; 2():221-9. PubMed ID: 7748304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin-altering medications and desire, consumption and effects of alcohol-treatment implications.
    Naranjo CA; Bremner KE
    EXS; 1994; 71():209-19. PubMed ID: 8032152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
    Meert TF
    Alcohol Alcohol; 1993 Mar; 28(2):157-70. PubMed ID: 8517886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers.
    Naranjo CA; Poulos CX; Bremner KE; Lanctôt KL
    Clin Pharmacol Ther; 1992 Jun; 51(6):729-39. PubMed ID: 1535302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive reduction of alcohol drinking by 5-HT1A antagonist WAY 100635 and serotonin uptake blocker fluoxetine in alcohol-preferring P rats.
    Zhou FC; McKinzie DL; Patel TD; Lumeng L; Li TK
    Alcohol Clin Exp Res; 1998 Feb; 22(1):266-9. PubMed ID: 9514317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medications acting on the serotonergic system for the treatment of alcohol dependent patients.
    Kenna GA
    Curr Pharm Des; 2010; 16(19):2126-35. PubMed ID: 20482508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine attenuates alcohol intake and desire to drink.
    Naranjo CA; Poulos CX; Bremner KE; Lanctot KL
    Int Clin Psychopharmacol; 1994 Sep; 9(3):163-72. PubMed ID: 7814825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram.
    Stenfors C; Yu H; Ross SB
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):222-32. PubMed ID: 11218075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible pharmacological probes for predicting and preventing relapse in treated alcoholics.
    Naranjo CA; Kadlec KE
    Alcohol Alcohol Suppl; 1991; 1():523-6. PubMed ID: 1845592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment.
    Johnson BA
    CNS Drugs; 2004; 18(15):1105-18. PubMed ID: 15581381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and alcohol drinking.
    Sellers EM; Higgins GA; Tompkins DM; Romach MK
    NIDA Res Monogr; 1992; 119():141-5. PubMed ID: 1435969
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.
    Naranjo CA; Knoke DM
    J Clin Psychiatry; 2001; 62 Suppl 20():18-25. PubMed ID: 11584871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT2C receptors inhibit and 5-HT1A receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy.
    Jakus R; Graf M; Juhasz G; Gerber K; Levay G; Halasz P; Bagdy G
    Exp Neurol; 2003 Dec; 184(2):964-72. PubMed ID: 14769389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
    Arborelius L; Nomikos GG; Hertel P; Salmi P; Grillner P; Höök BB; Hacksell U; Svensson TH
    Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):630-40. PubMed ID: 8738296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism.
    Lejoyeux M
    Alcohol Alcohol; 1996 Mar; 31 Suppl 1():69-75. PubMed ID: 8737004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
    van Amsterdam C; Seyfried CA
    Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
    Maurel S; De Vry J; Schreiber R
    Alcohol; 1999 Apr; 17(3):195-201. PubMed ID: 10231167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat.
    Lucas G; Du J; Romeas T; Mnie-Filali O; Haddjeri N; Piñeyro G; Debonnel G
    PLoS One; 2010 Feb; 5(2):e9253. PubMed ID: 20169084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on nociception of the Ca2+ and 5-HT antagonist dotarizine and other 5-HT receptor agonists and antagonists.
    Belcheva S; Petkov VD; Konstantinova E; Petkov VV; Boyanova E
    Acta Physiol Pharmacol Bulg; 1995; 21(4):93-8. PubMed ID: 8830881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo inhibitory effect of the 5-HT uptake blocker citalopram on 5-HT synthesis.
    Moret C; Briley M
    J Neural Transm (Vienna); 1997; 104(2-3):147-60. PubMed ID: 9203078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.